News & Analysis on Clinical Trial Services & Contract Research And Development
The US FDA is allowing Fresenius Kabi USA to import trace elements and phosphate injections from its Norway plant to help improve a critical shortage of components of total parenteral nutrition (TPN).
3M says it has cooperated with the FDA and invested in its facilities in preparation of the phase-out of CFC containing metered dose inhalers (MDIs).
GlaxoSmithKline has brought its vaccine development in-house with the purchase of Okairos and its supplementary technology platform.
UPM Pharmaceuticals will acquire Pfizer’s commercial manufacturing facility in Bristol, Tennessee to scale up its capacity as a contract manufacturer.